Medpace Growth Trends Show How CRO Demand Is Shifting in 2026

Medpace Holdings is reporting a shift in clinical research organization (CRO) demand for 2026, characterized by uneven growth across therapeutic areas and a lengthening award-to-revenue conversion cycle. While metabolic and GLP-1 programs are providing stability with lower cancellation rates, the oncology and cardiovascular sectors are experiencing increased volatility that impacts forward visibility. These trends highlight a broader industry transition where operational discipline and technology investments are becoming critical to maintaining margins amidst normalizing demand patterns.

Medpace’s recent performance underscores a divergence in therapeutic demand, with metabolic and GLP-1 programs acting as a stabilizing force due to historically lower cancellation rates. In contrast, the oncology and cardiovascular sectors have emerged as primary sources of recent cancellations, creating pressure on visibility for these core components of the clinical-development base. This unevenness is a key indicator for the broader clinical services group, including peers like IQVIA Holdings, as sponsor spending patterns shift away from traditional strongholds toward high-growth metabolic indications.

The company reported first-quarter EBITDA of $149.4 million with a margin of 21.1%, nearly matching the 21.2% recorded in the previous year despite a high volume of reimbursed out-of-pocket activity. Pass-through revenues accounted for approximately 44% of total revenue during the quarter, which can complicate year-over-year growth comparisons. While Medpace expects between $1.9 billion and $1.94 billion of its backlog to convert into revenue over the next 12 months, the first-quarter net book-to-bill ratio stood at 0.88X, reflecting a more measured pace of new business.

A significant challenge facing the CRO sector is the widening gap between initial award notifications and active project starts, with Medpace noting that awards now typically take three to five quarters to begin. This delayed conversion cycle suggests that while pipeline activity is improving, it will support long-term growth rather than immediate revenue acceleration. Furthermore, Medpace is heavily investing in artificial intelligence, though these costs are expected to exceed realized savings through 2027. This strategy mirrors trends at companies like Charles River Laboratories, where upfront technology absorption is necessary before automation and analytics can deliver measurable operating leverage.